Although osimertinib, as a third-generation and irreversible TKI, is now the front-line treatment for EGFR mutant NSCLC with superior central nervous system and survival outcomes [19,20], tumour relapse is inevitable. This evidence concerns the gene EGFR and non-small cell lung carcinoma.